Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation

Brain Tumor Pathology

Volumn 30, Issue 3, 2013, Pages 175-179

  Yoshikawa, Akifumi ^a   Nakada, Mitsutoshi ^a   Watanabe, Takuya ^a   Hayashi, Yutaka ^a   Sabit, Hemragul ^a   Kato, Yukinari ^b   Suzuki, Shioto ^c   Ooi, Akishi ^c   Sato, Hiroshi ^a   Hamada, Jun Ichiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Adult; IDH 1; Medulla oblongata; MGMT; Primary glioblastoma

Indexed keywords

GADOLINIUM; GLIAL FIBRILLARY ACIDIC PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; ANOREXIA; ARTICLE; AUTOPSY; CASE REPORT; CHEMORADIOTHERAPY; CONTRAST ENHANCEMENT; DEATH; DISEASE COURSE; DIZZINESS; FEMALE; GAIT DISORDER; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; KARNOFSKY PERFORMANCE STATUS; MEDULLA OBLONGATA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROMOTER REGION;

BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DISEASE PROGRESSION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FATAL OUTCOME; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MAGNETIC RESONANCE IMAGING; MEDULLA OBLONGATA; METHYLATION; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84880832424     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-012-0118-9     Document Type: Article

References (26)

1. Henson JW (2006) Treatment of glioblastoma multiforme: a new standard. Arch Neurol 63:337-341
2. Stark AM, Maslehaty H, Hugo HH et al (2010) Glioblastoma of the cerebellum and brainstem. J Clin Neurosci 17:1248-1251
3. Queiroz Lde S, da Cruz Neto JN, Lopes de Faria J (1974) Glioblastoma multiforme of the medulla oblangata. Acta Neuropathol 29:355-360
4. Yoshimura J, Onda K, Tanaka R et al (2003) Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. Neurol Med Chir (Tokyo) 43:375-382 (discussion 382)
5. Luetjens G, Mirzayan MJ, Brandis A et al (2009) Exophytic giant cell glioblastoma of the medulla oblongata. J Neurosurg 110:589-593
6. Kyoshima K, Sakai K, Goto T et al (2004) Gross total surgical removal of malignant glioma from the medulla oblongata: report of two adult cases with reference to surgical anatomy. J Clin Neurosci 11:75-80
7. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
8. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
9. Rivera AL, Pelloski CE, Gilbert MR et al (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12:116-121
10. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
11. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
12. Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707-718
13. Yoshida Y, Nakada M, Harada T et al (2010) The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol 98:41-47
14. Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007
15. Misaki K, Nakada M, Mohri M et al (2011) MGMT promoter methylation and temozolomide response in choroid plexus carcinoma. Brain Tumor Pathol 28:259-263
16. Guillamo JS, Doz F, Delattre JY (2001) Brain stem gliomas. Curr Opin Neurol 14:711-715
17. Nishio S, Fukui M, Tateishi J (1988) Brain stem gliomas: a clinicopathological analysis of 23 histologically proven cases. J Neurooncol 6:245-250
18. Selvapandian S, Rajshekhar V, Chandy MJ (1999) Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults. Acta Neurochir (Wien) 141:721-726 (discussion 726-727)
19. Kesari S, Kim RS, Markos V et al (2008) Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. J Neurooncol 88:175-183
20. Tokuriki Y, Handa H, Yamashita J et al (1986) Brainstem glioma: an analysis of 85 cases. Acta Neurochir (Wien) 79:67-73
21. Guillamo JS, Monjour A, Taillandier L et al (2001) Brainstem gliomas in adults: prognostic factors and classification. Brain 124:2528-2539
22. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453
23. Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1:44-51
24. Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153
25. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341-347
26. von Deimling A, Korshunov A, Hartmann C (2011) The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21:74-87